USA –Mary J Blige is set to embark on a 23-city Good Morning Gorgeous tour, which will feature stops in New York and Los Angeles and has teamed with Hologic to raise health awareness for women of color.
Afrotech reports the tour will be presented by Hologic in partnership with the Black Promoters Collective (BPC).
Hologic is a medical technology innovator working to improve women’s health through screenings for treatment and revolutionizing daily care.
The company is home to the world’s first commercial 3D mammography system and is a leader in testing for cervical cancer, respiratory illnesses and COVID-19.
“We’re thrilled to continue our partnership with Mary J. Blige as the presenting sponsor for her Good Morning Gorgeous tour,” Hologic’s Chairman, President, and Chief Executive Officer Steve MacMillan, according to A release.
“As a global leader in women’s health, we’re committed to emphasizing the lifesaving importance of preventive screenings and the annual Well Woman exam, and Mary’s voice is a powerful way to reach millions of women.”
Women of color are the second most likely demographic to be diagnosed with cervical cancer.
Blige, whose tour will include special appearances from Ella Mai and Queen Naija, has partnered with Hologic for its “Her Wealth is Her Health” commercial earlier this year.
She also spoke on her own health and the stigma behind people of color and health during a “Screening the System: A Dialogue on Bias and Breast Health panel hosted by Hologic, according to the outlet.
“I had an aunt who died of breast cancer. My grandmother died from cervical cancer and another aunt died of lung cancer,” Blige said.
“Nobody spoke about it at home. That’s why they ended up in the hospital with two weeks to live, and NOW we’re talking about it. I know this is happening in a lot of African American homes, and that’s why we need to talk about it.”
According to Medical News Today, women of color are the second most likely demographic to be diagnosed with cervical cancer.
Additionally, women of color are 80% more likely to die from cervical cancer than White women.
Meanwhile, Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp, a leading global life sciences company have announced a new collaboration to increase clinical trial diversity for women of color and co-create health equity solutions.
Labcorp has signed Tigerlily’s #InclusionPledge for Women of color, joining other healthcare and life sciences companies in pledging to remove barriers to cancer care and research for women of color.
Tigerlily and Labcorp will collaborate to eliminate health disparities through the #InclusionPledge. This collaboration aims to find solutions to promote health equity among women of color and to break down barriers that have made access to clinical trials difficult.
Elsewhere, according to GlobalData, India had the third-highest increase in total HER2+ breast cancer cases among 16 markets worldwide.
According to the leading data and analytics firm, total incident cases in the country are expected to rise from 255,749 in 2022 to 311,128 by 2030 at a 2.84 percent annual growth rate (AGR).
To address this growing challenge, the Indian government and organizations are developing digital campaigns to raise awareness of the early signs of the disease, according to GlobalData.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
